The critical blend of science and finance for bioscience businesses
Leaders in the life sciences and bioscience sectors share insights
At a recent CBI Finance and Accounting for Bioscience Companies conference, RSM hosted a roundtable panel discussion on the role of the finance leader in scaling bioscience businesses. Panelists from the industry shared best practices and thoughts on:
- How to stay on top of the latest financial and science insights
- The importance of telling the company’s story in terms of investors, stakeholders and potential business partners
- The challenges and opportunities when managing third-party providers
Stressing the importance of making sure both science and finance functions are working in tandem, one panelist indicated, “If we’re going to develop therapeutic solutions that improve the quality of life and health of people, we’ve got to be financially and operationally healthy as well.”
To get more of the discussion, download Pharmaceutical Executive’s article, “Science & finance: The biotech blend,” which includes edited excerpts from the event. The panel was facilitated by RSM’s John Lanza, national life sciences practice leader, and Nancy Aubrey, a partner in RSM’s risk advisory services.
For related content, check out the following:
Understand the risks associated with life sciences third party management and how to proactively mitigate them in a responsible manner.
What were the important takeaway topics from CBI’s Finance & Accounting for Biosciences Conference? Read our recap.
Learn how outsourcing can help life sciences organization establish a strong foundation for current and sustained success.